Katherine Ann Devitt

Katherine Ann Devitt

Auto-generated profile, based on publicly available information

Katherine Ann Devitt

Department of Pathology and Laboratory Medicine University of Vermont Medical Center Burlington Vermont USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2024 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
PDF file
KDKatherine A. Devitt
Katherine A. Devitt
WKWolfgang Kern
Wolfgang Kern
WLWeijie Li
Weijie Li
XWXuehai Wang
Xuehai Wang
AWAllyson J. Wong
Allyson J. Wong
AIAndrea Illingworth
Andrea Illingworth
The assessment of T‐cell clonality by flow cytometry has long been suboptimal, relying on aberrant marker expression and/or intensity. The introduction of TRBC1 shows much promise for improving the diagnosis of T‐cell neoplasms in the clinical flow laboratory. Most laboratories considering this marker already have existing panels designed for T‐cell workups and will be determining how best to incorporate TRBC1. We present this comprehensive summary of TRBC1 and supplemental case examples to familiarize the flow cytometry community with its potential for routine application, provide examples of how to incorporate it into T‐cell panels, and signal caution in interpreting the results in certain diagnostic scenarios where appropriate.

22 October 2025 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
JOJean Oak
Jean Oak
FFFelipe Magalhaes Furtado
Felipe Magalhaes Furtado
KDKatherine A. Devitt
Katherine A. Devitt
PHPedro Horna
Pedro Horna
JFJonathan R. Fromm
Jonathan R. Fromm
MSMin Shi
Min Shi
The diagnosis of T‐cell neoplasms remains one of the most challenging areas in hematopathology due to the immunophenotypic heterogeneity and subtle aberrancies often present in these entities. This “Best Practice” manuscript provides a practical framework for laboratories to design, validate, and interpret immunophenotyping studies of immature and mature T‐cell neoplasms. We outline the utility of key antigens in the screening and classification of T‐cell lymphomas/leukemia including TRBC1 and TRBC2. Analytical strategies using the “difference from normal” method and template‐based gating are discussed, along with validation considerations aligned with CLSI H62 guidelines. By integrating these principles into laboratory workflows, this manuscript aims to standardize and improve the assessment of T‐cell neoplasms across diverse clinical settings.

1 January 2018 in Autopsy Case Reports
Verified
Journal Article
Open access
PDF file
KDKatherine Ann Devitt
Katherine Ann Devitt
JGJuli-Anne Gardner
Juli-Anne Gardner
Autops Case Rep, vol.8, n4, e2018055, 2018

20 July 2024 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
KDKatherine A. Devitt
Katherine A. Devitt
WKWolfgang Kern
Wolfgang Kern
MKMalgorzata A. Kajstura
Malgorzata A. Kajstura
EHEda K. Holl
Eda K. Holl
AHAmanda L. Hays
Amanda L. Hays
MOMadhu M. Ouseph
Madhu M. Ouseph
The publication of Clinical and Laboratory Standards Institute's guideline H62 has provided the flow cytometry community with much‐needed guidance on development and validation of flow cytometric assays (CLSI, 2021). It has also paved the way for additional exploration of certain topics requiring additional guidance. Flow cytometric analysis of rare matrices, or unique and/or less frequently encountered specimen types, is one such topic and is the focus of this manuscript. This document is the result of a collaboration subject matter experts from a diverse range of backgrounds and seeks to provide best practice consensus guidance regarding these types of specimens. Herein, we define rare matrix samples in the setting of flow cytometric analysis, address validation implications and challenges with these samples, and describe important considerations of using these samples in both clinical and research settings.

1 January 2021 in Autopsy Case Reports
Verified
Journal Article
Open access
PDF file
FEFrederick Eyerer
Frederick Eyerer
JGJuli-Anne Gardner
Juli-Anne Gardner
KDKatherine A. Devitt
Katherine A. Devitt
Autops Case Rep, vol.11, e2021340, 2021

1 January 2019 in Autopsy Case Reports
Verified
Journal Article
Open access
TRThomas S Rogers
Thomas S Rogers
JGJuli-Anne Gardner
Juli-Anne Gardner
KDKatherine A Devitt
Katherine A Devitt
Richter transformation (RT), or Richter syndrome, is defined as the transformation of chronic lymphocytic leukemia (CLL) to an aggressive B-cell lymphoma. The vast majority, up to 99%, transform into diffuse large B-cell lymphoma (DLBCL), with a small subset (<1%) becoming classical Hodgkin lymphoma. Approximately half of RT cases progress through a pathway involving dysregulation of C-MYC. High-grade B-cell lymphoma (HGBL) is a recent diagnostic category of aggressive B-cell lymphomas set forth in the updated 2017 WHO Classification of Hematopoietic and Lymphoid Tissues. HGBL with MYC and BCL2 and/or BCL6 rearrangements, formerly "double-hit" and "triple-hit" lymphomas, comprise the majority of HGBL cases. Patients with HGBL have a worse prognosis than those with diffuse large B-cell lymphoma. We present a case of RT with rearrangements of MYC and BCL6. To our knowledge, there are no reported cases of RT with a "double-hit" lymphoma genotype.